Uma Borate: Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS?

Uma Borate, Acute Leukemia Translation Lead, Associate Professor at OHSU, shared on X:

“Fantastic start to ALFlive24 at Medscape LIVE with a clinically relevant debate amongst the greatest minds in MDS Rami Komrokji and Guillermo Garcia-Manero– Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS? What do you think ?- Vote”

Source: Uma Borate/X